The following is a list of initial public offerings that priced during the week of Mar. 1-5.
Anthera Pharmaceuticals Inc. (Nasdaq: ANTH), a Hayward, Calif.-based biotech which is developing anti-inflammatory therapeutics for cardiovascular diseases, lupus and other serious diseases, priced 6 million shares at $7 each on March 1. The deal was delayed on Feb. 24, as the company revised terms from 4.6 million shares, priced $13 to $15, to 5.5 million shares priced $8 to $9. Deutsche Bank Securities was the lead manager. The stock closed the first day, Monday, at $7.01, and ended the week at $7.00, unchanged from the offering price.